Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FJUT3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,969
Award facts
- Contract value 100% obligated
- $20,969.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, valued at $20,969.28 under a firm fixed-price contract type, was awarded on November 18, 2025, with an ultimate completion date of December 10, 2025. No set-aside designation was used in this procurement. DMS Pharmaceutical Group Inc. is performing the work at its Park Ridge, Illinois facility and will deliver this biologic immunosuppressant medication to support Department of Defense healthcare requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), which was awarded on November 13, 2025, with a $499.999 billion ceiling and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion federal acquisition strategy establishing multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across diverse therapeutic categories, including specialty pharmaceuticals and biologics, positions the company as a critical supplier within the Department of Defense's global medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FJUT3?
SPE2DR26FJUT3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FJUT3 worth?
The government has obligated $20,969 on SPE2DR26FJUT3.
Is contract SPE2DR26FJUT3 an order under another contract?
Yes. SPE2DR26FJUT3 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUT3 competed?
The extent of competition for SPE2DR26FJUT3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award